Cancer is a disease that is attributed to the uncontrollable spread and growth of abnormal cells. Throughout the world, cancer is the second most deadly illness that causes death. As of 2022, in India, 100.4 people in 1,00,000 suffer from cancer and 1 in every 9 people is likely to develop cancer at some point throughout their lives. The morbidity spread by cancer is one of the most prolific of all diseases and has been the centre of attention of researchers and pharmaceutical companies for decades. Over the years, cancer treatment, through the means of custom gene therapy and biological solutions has been available worldwide. However, the majority of it has remained outside the reach of the common people or is not readily available in lesser-developed countries of Asia and Africa.

There is a major need for the development of readily available cancer treatment solutions at affordable prices. Cancer drug manufacturing companies in India have devoted their effort and resources to the delivery of therapeutics and diagnostics, and suffice to say, they have come a long way. Among these companies, Venus Remedies has managed to be a top oncology pharmaceutical company in India.

Our Research into Oncology

The Venus Medical Research Centre has dedicated its resources and effort to researching the lacking needs of all throughout India and has been developing therapeutic approaches for anticancer theragnostic. The primary target for our cancer research centre has been on multi-purpose approaches such as Drug Protein Polymer Conjugate or DPPC, along with targeting Stealth Targeted Nano-delivery or STN nanotechnologies for the treatment of cancer. All of this has the combined aim of manufacturing and distributing oncology drugs with a minimum level of systemic toxicity. As one of the top oncology pharma companies in India, we aim to reduce the cost of cancer treatment by increasing the effectiveness of oncology drugs and reducing the frequency of administration needed.

A New Approach to Cancer Treatment

Cancer is commonly seen as a disease that once has been diagnosed, spells the inevitable demise of the individual. Often, it is thought to be a disease that has no cure. Although there is yet to be a perfect cure for cancer that has reached the later and more deadly stages, if diagnosed early on, it can be cured. According to the National Cancer Institute, the survival rate of patients 5 years after they have been diagnosed is 68.7%.. However, cancer remains one of the top causes of mortality, globally. A major reason is that, for a long time, the same model of treatment has been used to approach cancer cases. Rather than having a generalised approach, individual treatment, and multifaceted interventions serve as the key to the future of oncology. A major means through which the Venus Medicine Research Centre has contributed to the field of oncology is through the development of site-specific drugs that have reduced side effects. By having drugs that specifically target cancer cells in the afflicted organ a more effective form of treatment can be administered while also being able to keep the cost of treatment low and affordable.

Our approach

Over the years we have managed to become one of the top oncology pharma companies through the development of a new solution for the unmet medical need. One of our top oncology drugs, Taxedol, has been launched as single-dose injectable vials. The primary component of the drug is Docetaxel which makes the vial formula easier to administer, whether directly into an infusion bag or a premix solution. Taxedol has proven to have a higher affinity when it comes to the targeting of cancer cells and killing them compared to other Docetaxel medications. Additionally, the time it takes for the drug to take effect is significantly shorter than for other drugs, while also offering a deeper spread of the drug. The drug is able to be used for a variety of oncological conditions:

• Gastric Adenocarcinoma
• Prostate cancer
• Non-Small Cell Lung Cancer
• Neck and Head Cancer
• Breast Cancer

With teams of scientists at Venus Remedies Limited focused on target-based drug delivery treatment for cancer, the current approach is DPPC. Through this approach, oncological treatment can be expedited through the identification of the target organ, based on which different aspects of DPPC can be selected as the optimal course of treatment. Such an approach bear with it the benefits of having:

• The minimal reaction of normal cells against the active while increases the influx of reactivity with the target organ cells.
• Higher efficiency and specificity of drug delivery in a defined set of cells of cancer affects organs.
• Reduces frequency of adminisṣtration and drug quantity compared to selective and individual use of identified protein-polymer conjugate.
• Reduced risk side effect development, while also increasing the availability of the drug at the targeted organ through continuous release.
• Better patient compliance through having the oncology drugs administered as a single dose through an IV.

Accreditations:

It has been our tireless efforts over the past years that have allowed us to claim the title of a top oncology medicine manufacturer in India. The efforts of all of the researchers have been recognised by global regulatory authorities. This has also allowed us to gain, both, national and global endorsements with the manufacturing facilities gaining over 20 GMP approvals. Some of our worldwide accreditations have been bestowed by the:

• Drug Regulatory Unit of Botswana
• Pharmacy and Poison Board of Kenya
• Saudi Food and Drug Authority
• National Drug Authority of Uganda
• Ukraine Ministry of Health
• Yemen Ministry of Health
• Ministry of Health- UAE
• Ministry of Health- Iran.

Each of these accreditations has allowed Venus to reach new heights, especially in the field of oncology.

With the advancement of technology, a great understanding of health and treatment gets unlocked. While there is much more to learn about the spread and effects of cancer, through consistent research and innovation, more effective drugs and treatment methods are being devised. Venus has always aimed to spearhead innovation in finding new effective approaches in the field of oncology. In recent years, we have managed to gain market authorization from the United Kingdom for Cisplatin. With this included, Venus currently has managed to gain over 800 marketing authorizations from different countries all over the world. We shall continuously strive to live up to the title of being one of the top oncology pharma companies in India and make cancer treatment drugs more effective and available for the masses.

Sources:

• https://journals.lww.com/ijmr/Fulltext/2022/10000/Cancer_incidence_estimates_for_2022___projection.6.aspx#:~:text=Results%3A,in%20males%20and%20females%2C%20respectively
• https://venusremedies.com/taxedol
• https://venusremedies.com/accreditation
• https://www.cnbctv18.com/healthcare/venus-remedies-secures-marketing-authorisation-from-uk-mhra-for-cisplatin-oncology-chemotherapy-drug-cancer-drug-16492331.htm